[
    [
        {
            "time": "",
            "orginal_text": "康龙化成：新药研发“卖铲人”，未来前景如何？",
            "features": {
                "keywords": [
                    "康龙化成",
                    "新药研发",
                    "卖铲人",
                    "未来前景"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "康龙化成：新药研发“卖铲人”，未来前景如何？",
            "scores": {
                "News_content": "康龙化成：新药研发“卖铲人”，未来前景如何？",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "orginal_text": "药明康德、泰格医药、凯莱英等CRO龙头同样也存在着被股东持续减持的潜在情形。 减持股份数量。",
            "features": {
                "keywords": [
                    "药明康德",
                    "泰格医药",
                    "凯莱英",
                    "CRO",
                    "减持"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "药明康德、泰格医药、凯莱英等CRO龙头同样也存在着被股东持续减持的潜在情形。 减持股份数量。",
            "scores": {
                "News_content": "药明康德、泰格医药、凯莱英等CRO龙头同样也存在着被股东持续减持的潜在情形。 减持股份数量。",
                "Correlation": 7,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "orginal_text": "高瓴早已洞穿趋势！CXO最重磅的未来，不在于大分子CDMO！",
            "features": {
                "keywords": [
                    "高瓴",
                    "CXO",
                    "大分子CDMO",
                    "未来趋势"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "高瓴早已洞穿趋势！CXO最重磅的未来，不在于大分子CDMO！",
            "scores": {
                "News_content": "高瓴早已洞穿趋势！CXO最重磅的未来，不在于大分子CDMO！",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "orginal_text": "康龙化成(03759-HK)获摩根士丹利增持40.9505万股",
            "features": {
                "keywords": [
                    "康龙化成",
                    "摩根士丹利",
                    "增持"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "康龙化成(03759-HK)获摩根士丹利增持40.9505万股",
            "scores": {
                "News_content": "康龙化成(03759-HK)获摩根士丹利增持40.9505万股",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 7,
                "Duration": 4,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 10
            }
        },
        {
            "time": "",
            "orginal_text": "医药行业一周观察：继续推荐成长性确定且估值合理的优质标的",
            "features": {
                "keywords": [
                    "医药行业",
                    "成长性",
                    "估值合理",
                    "优质标的"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "医药行业一周观察：继续推荐成长性确定且估值合理的优质标的",
            "scores": {
                "News_content": "医药行业一周观察：继续推荐成长性确定且估值合理的优质标的",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "orginal_text": "华金证券维持康龙化成增持评级：业绩符合预期，持续扩大产业版图",
            "features": {
                "keywords": [
                    "华金证券",
                    "康龙化成",
                    "增持评级",
                    "业绩符合预期",
                    "产业版图"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "华金证券维持康龙化成增持评级：业绩符合预期，持续扩大产业版图",
            "scores": {
                "News_content": "华金证券维持康龙化成增持评级：业绩符合预期，持续扩大产业版图",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "orginal_text": "康龙化成：全年业绩高增，一体化竞争优势凸显【东吴医药朱国广团队】",
            "features": {
                "keywords": [
                    "康龙化成",
                    "全年业绩高增",
                    "一体化优势",
                    "东吴医药"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "康龙化成：全年业绩高增，一体化竞争优势凸显【东吴医药朱国广团队】",
            "scores": {
                "News_content": "康龙化成：全年业绩高增，一体化竞争优势凸显【东吴医药朱国广团队】",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "orginal_text": "安信证券给予康龙化成买入评级：一体化平台优势明显，技术进步驱动成长",
            "features": {
                "keywords": [
                    "安信证券",
                    "康龙化成",
                    "买入评级",
                    "一体化平台",
                    "技术进步"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "安信证券给予康龙化成买入评级：一体化平台优势明显，技术进步驱动成长",
            "scores": {
                "News_content": "安信证券给予康龙化成买入评级：一体化平台优势明显，技术进步驱动成长",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "orginal_text": "康龙化成2020年净利润增长110%以上 财报密集期多家公司业绩向好",
            "features": {
                "keywords": [
                    "康龙化成",
                    "2020年",
                    "净利润增长",
                    "财报密集期"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "康龙化成2020年净利润增长110%以上 财报密集期多家公司业绩向好",
            "scores": {
                "News_content": "康龙化成2020年净利润增长110%以上 财报密集期多家公司业绩向好",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 7,
                "Duration": 4,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "orginal_text": "康龙化成年报深度点评：各业务板块发展势头良好，致力成为多疗法药物研发服务全球领军企业",
            "features": {
                "keywords": [
                    "康龙化成",
                    "年报",
                    "业务板块",
                    "多疗法药物研发",
                    "全球领军企业"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "康龙化成年报深度点评：各业务板块发展势头良好，致力成为多疗法药物研发服务全球领军企业",
            "scores": {
                "News_content": "康龙化成年报深度点评：各业务板块发展势头良好，致力成为多疗法药物研发服务全球领军企业",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        }
    ]
]